GlassScriptPhysician profile
Yola Augustin
NPI 1144282278
$12,358.09
in general payments reported to CMS, 2019-2025
53 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,060 · 2020: $1,376 · 2021: $2,399 · 2022: $1,487 · 2023: $1,573 · 2024: $1,615 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,036.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,538.94 | 2019-2025 | Vraylar, Ubrelvy, Mavyret |
| Glaxosmithkline, LLC. | $1,464.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $1,030.88 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $956.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $876.34 | 2019-2025 | |
| Allergan, INC. | $810.88 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $796.23 | 2021-2025 | |
| Gilead Sciences, INC. | $498.17 | 2023-2025 | Yeztugo, Descovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.66 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $316.75 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $293.09 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $275.04 | 2019-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Lilly USA, LLC | $242.73 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $218.14 | 2019-2025 | Evenity, Prolia, Repatha |
| Shield Therapeutics INC | $215.86 | 2023-2025 | Accrufer |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yola Augustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.